Table 1.
Characteristics of the Donors.
| Criteria\Donor | SSc01 | SSc02 | SSc03 | SSc04 | SSc05 | SSc06 | SSc07 | SSc08 | HS (n = 11) |
|---|---|---|---|---|---|---|---|---|---|
| Gender | F | F | F | M | M | F | F | F | F |
| Ethnicity | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian (10/11) |
| Patient age | 37 | 63 | 81 | 54 | 48 | 54 | 39 | 50 | 47+/−9.5 |
| diffuse cutaneous SSc | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA |
| Disease Duration (months) | 11 | 14 | 5 | 2 | 4 | 4 | 4 | 2 | NA |
| First non-Raynaud symptoms (months prior skin collection) | 11 | 15 | 5 | 7 | 4 | 10 | 4 | 6 | NA |
| Raynaud manifestations | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA |
| Modified Rodnan skin score | 7/51 | 31/51 | 13/51 | 29/51 | 37/51 | 14/51 | 21/51 | 18/51 | NA |
| Auto-antibodies | PmScl | fibrillarin/U3 RNP | Topoisomerase (Scl-70) | Topoisomerase (Scl-70) | Topoisomerase (Scl-70) | Topoisomerase (Scl-70) | fibrillarin | RNA pol III | NA |
| Treatment | Hydroxychloroquine Prednisone Methotrexate | No immuno-suppressive therapy | No immuno-suppressive therapy | No immuno-suppressive therapy | Methotrexate (3 wks) | No immuno-suppressive therapy | Methotrexate (2 months) | Methotrexate (day of biopsy collection) | NA |